INJECTAPAP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for INJECTAPAP (INJECTAPAP).
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
| Metabolism | Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione. |
| Excretion | Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%). |
| Half-life | 2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment. |
| Protein binding | 10-25% bound to albumin at therapeutic concentrations. |
| Volume of Distribution | 0.8-1.0 L/kg; suggests distribution into total body water. |
| Bioavailability | IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%. |
| Onset of Action | IV: 5-10 minutes; oral: 30-60 minutes. |
| Duration of Action | Analgesic/antipyretic effects: 4-6 hours. Duration may be shorter with IV administration due to rapid distribution. |
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 30-60 mL/min: no adjustment; for GFR <30 mL/min: extend interval to every 8 hours; maximum 3 g per day. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated. |
| Pediatric use | For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous. |
| Geriatric use | No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for INJECTAPAP (INJECTAPAP).
| Breastfeeding | Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration. |
| Teratogenic Risk | FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity. |
■ FDA Black Box Warning
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
| Serious Effects |
["Hypersensitivity to acetaminophen or any component of the formulation"]
| Precautions | ["Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment","Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis","Hypersensitivity reactions","Use caution in patients with G6PD deficiency","Avoid use with other acetaminophen-containing products"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal liver function tests (ALT, AST) in cases of prolonged use or overdose. Fetal monitoring via ultrasound for growth restriction if chronic high-dose use. No specific fetal monitoring required for standard doses. |
| Fertility Effects | No known adverse effects on fertility. Acetaminophen has not been shown to impair male or female fertility at therapeutic doses. |